Innovent Biologics, Inc. IVBXF
11.31 USD +1.24 (+12.31%)
At closeNov 4, 2026, 4:00 PM EST
10.35 Day range 10.35
9.10 52-week range 15.01
- YTD
- +16.00%
- 1 year
- +6.20%
- Market cap
- 19.72B
- EPS (ttm)
- 0.10
- P/E ratio
- 113.10
- YTD return
- +16.00%
- 1-year return
- +6.20%
- Volume
- 500
- Avg volume
- 2.02K
- Open
- 10.35
- Previous close
- 10.07
- Day's range
- 10.35 – 10.35
- 52-week range
- 9.10 – 15.01
- Earnings date
- Aug 26, 2026
2Y +4.96 (+97.06%)
Next earnings
Aug 26, 2026
Expected Aug 26, 2026. Consensus EPS estimate 0.06917.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 26, 2026 | Jun 30, 2026 | 0.06917 | — | — | — |
| Mar 26, 2026 | Dec 31, 2025 | 0.01716 | -0.00143 | -0.02 | -108.33% |
| Aug 27, 2025 | Jun 30, 2025 | 0.02512 | 0.06865 | +0.04 | +173.29% |
| Mar 26, 2025 | Dec 31, 2024 | -0.0315 | 0.02501 | +0.06 | +179.40% |
| Aug 28, 2024 | Jun 30, 2024 | -0.03439 | -0.03329 | 0.00 | +3.20% |
| Mar 20, 2024 | Dec 31, 2023 | -0.07042 | -0.07922 | -0.01 | -12.50% |
News
Innovent, Eli Lilly Partner to Commercialize Breast Cancer Drug in China 
China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug 
Pfizer, Innovent GLP-1 drugs pass China insurance preliminary review 
Innovent's Partner Ollin Biosciences Announces Oversubscribed $330 Million Series B Financing to Advance Global Phase 3 Development of IBI324 (OLN324) in DME and Wet AMD; Studies Commencing in Second Half of 2026 
Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma 
Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion 
China's Innovent Biologics, Pfizer strike up to $10.5 billion cancer drug deal 
2026 ASCO Abstract Highlights | Innovent Announces Preliminary PoC data of IBI363 (PD-1/IL-2α-bias bispecific fusion protein) in Combination with Chemotherapy as First-line Treatment for Advanced NSCLC, Showing Encouraging Efficacy Signals and Favorable S 
2026 ASCO Abstract Highlights: Innovent Biologics' IBI363 (PD-1/IL-2α-bias bispecific fusion protein) Demonstrates Robust Survival Benefits in Long-Term Follow-up of PoC Study in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer 
Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
Your note
Sign in to keep a note on IVBXF — it syncs with the Stock Master app.